Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Laufer

Showing results (1-10 of 282) with videos related to

Pageof 29
Sort By:
Current Opinion in Rheumatology|September 10, 2003
Role of eicosanoids in structural degradation in osteoarthritisStefan Laufer
Expert Opinion on Investigational Drugs|July 2, 2003
International Conference on Inflammopharmacology -- VIII Side-Effects of Anti-inflammatory Drugs SymposiumStefan Laufer
Pharmazie in Unserer Zeit|April 30, 2002
[What's in the future? New NSAIDs]Stefan Laufer
ACS Medicinal Chemistry Letters|January 16, 2015
New Frontiers in Kinases: Second Generation Inhibitors-Going beyond CancerStefan Laufer
Molecules (Basel, Switzerland)|July 25, 2018
Special Issue: Kinase inhibitorsPierre Koch, Stefan Laufer
Methods in Molecular Biology (Clifton, N.J.)|July 21, 2010
Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitorsStefan Laufer, Sabine Luik
Expert Opinion on Therapeutic Patents|March 23, 2025
A patent review of CXCR7 modulators (2019-present)Thanigaimalai Pillaiyar, Stefan Laufer
Organic & Biomolecular Chemistry|January 26, 2008
Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activityStefan Laufer, Pierre Koch
Bioorganic & Medicinal Chemistry Letters|February 7, 2009
Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinaseStefan Laufer, Frank Lehmann
Journal of Medicinal Chemistry|May 21, 2010
Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitorsPierre Koch, Stefan Laufer
Pageof 29

Showing results (1-10 of 282) with videos related to

Sort By:
Pageof 29
Current Opinion in Rheumatology|September 10, 2003
Role of eicosanoids in structural degradation in osteoarthritisStefan Laufer
Expert Opinion on Investigational Drugs|July 2, 2003
International Conference on Inflammopharmacology -- VIII Side-Effects of Anti-inflammatory Drugs SymposiumStefan Laufer
Pharmazie in Unserer Zeit|April 30, 2002
[What's in the future? New NSAIDs]Stefan Laufer
ACS Medicinal Chemistry Letters|January 16, 2015
New Frontiers in Kinases: Second Generation Inhibitors-Going beyond CancerStefan Laufer
Molecules (Basel, Switzerland)|July 25, 2018
Special Issue: Kinase inhibitorsPierre Koch, Stefan Laufer
Methods in Molecular Biology (Clifton, N.J.)|July 21, 2010
Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitorsStefan Laufer, Sabine Luik
Expert Opinion on Therapeutic Patents|March 23, 2025
A patent review of CXCR7 modulators (2019-present)Thanigaimalai Pillaiyar, Stefan Laufer
Organic & Biomolecular Chemistry|January 26, 2008
Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activityStefan Laufer, Pierre Koch
Bioorganic & Medicinal Chemistry Letters|February 7, 2009
Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinaseStefan Laufer, Frank Lehmann
Journal of Medicinal Chemistry|May 21, 2010
Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitorsPierre Koch, Stefan Laufer
Pageof 29